6-Thioguanine Suppresses EV71 Replication via BIRC3-Autophagy Axis

Study Background and Research Question

Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), predominantly affecting young children and capable of leading to severe neurological complications and fatalities. Despite the availability of vaccines targeting specific EV71 genotypes, there remains a lack of effective, broadly applicable antiviral therapeutics for EV71 infection in clinical practice (paper). Prior research has revealed that 6-thioguanine (6-TG), a thiopurine drug approved for cancer and inflammatory disease, also exhibits antiviral activity against viruses such as SARS-CoV-2 and influenza A. However, its effects on EV71 replication and the underlying mechanisms were not well characterized. The central question addressed by You et al. (2025) is whether 6-TG inhibits EV71 and, if so, through which molecular pathways.

Key Innovation from the Reference Study

This study delivers a pivotal advance by identifying that 6-TG robustly inhibits EV71 replication in vitro through the downregulation of BIRC3—a regulator of autophagy—thereby attenuating the autophagic processes essential for viral proliferation (paper). The work establishes a mechanistic link between 6-TG action, BIRC3 expression, and autophagic flux during EV71 infection. Notably, the selectivity index (SI) of 6-TG against EV71 is substantially higher than that of ribavirin, a benchmark antiviral, indicating superior specificity and a potentially favorable safety margin.

Methods and Experimental Design Insights

The research team employed a suite of in vitro assays using HT-29 human colon adenocarcinoma cells infected with EV71. The experimental approach included:

• Quantification of EV71 mRNA and VP1 protein levels to assess viral replication.
• Determination of cytotoxicity (CC₅₀) and antiviral efficacy (IC₅₀) for 6-TG.
• Measurement of viral progeny production after treatment.
• Western blot and immunofluorescence to evaluate the expression of BIRC3 and autophagy-related markers.

The CC₅₀ of 6-TG exceeded 2000 μM, indicating low cytotoxicity, while the IC₅₀ for EV71 was 0.9302 μM (paper). The selectivity index (SI > 2150.1) far surpassed that of ribavirin (SI > 66.7), demonstrating a wide therapeutic window.

Protocol Parameters

• cell proliferation assay | 6-TG, IC₅₀ = 0.9302 μM | HT-29 cells, EV71 infection model | Identifies effective antiviral concentration with minimal cytotoxicity | paper
• cytotoxicity assay | CC₅₀ > 2000 μM | HT-29 cells | Verifies safety margin for 6-TG application | paper
• autophagy marker analysis | BIRC3 and LC3-II expression | EV71-infected HT-29 cells | Links reduced BIRC3 to autophagy suppression and antiviral effect | paper
• CDK inhibitor-based cell cycle modulation | Ribociclib succinate, ≥25.85 mg/mL in DMSO | HER2-positive breast cancer cell lines | Facilitates robust cell cycle arrest for antineoplastic agent screening | product_spec
• pH-dependent solubility assessment | Ribociclib succinate, 814.05 μg/mL at pH 1.2 | Simulated gastric conditions | Ensures protocol compatibility with acid-reducing agents | workflow_recommendation

Core Findings and Why They Matter

The data show that 6-TG markedly reduces EV71 mRNA, viral VP1 protein, and virus progeny levels, confirming direct inhibition of viral replication. Mechanistically, 6-TG treatment decreases the expression of BIRC3 (baculoviral IAP repeat containing 3), an E3 ubiquitin ligase implicated in the regulation of autophagy. This downregulation leads to attenuation of autophagic flux—a pathway hijacked by EV71 to facilitate replication—thus suppressing the infection (paper). The strong selectivity index underscores the potential of 6-TG as a candidate for further antiviral development. This study expands the landscape of antiviral strategies by targeting virus-induced autophagy and reveals a new use for an established antineoplastic agent in virology research, highlighting the broader potential of repositioning drugs with known safety profiles.

Comparison with Existing Internal Articles

While the primary focus of this study is antiviral, it shares conceptual and technical parallels with cancer research workflows that utilize cell proliferation assays, cell cycle regulation, and the application of small-molecule inhibitors. For example, articles such as "Applied Workflows and Optimization of LEE011 Succinate in Cancer Research" and "LEE011 Succinate: Workflow Optimization with a CDK Inhibitor" provide method-focused guidance on leveraging CDK4/6 inhibitors like ribociclib succinate (LEE011 succinate) for robust cell proliferation and cell cycle arrest in HER2-positive models. While 6-TG targets autophagy and BIRC3, and ribociclib succinate targets CDK4/6-mediated cell cycle progression, both approaches illustrate the value of pathway-focused inhibition—whether for antiviral or antineoplastic research purposes. These internal resources offer practical protocol templates and troubleshooting advice that could inform assay development for both viral and cancer cell models. Further, internal reviews on the pH-dependent solubility of ribociclib succinate (Assessing pH-Dependent Interactions of Ribociclib Succinate in Cancer Research) provide insight into optimizing compound delivery and stability, a consideration relevant for both antiviral and cancer research workflows using small-molecule inhibitors.

Limitations and Transferability

The findings are based on in vitro assays using a single human cell line (HT-29), which may not fully recapitulate the complexity of EV71 infection in vivo or in other tissue types. The use of 6-TG as an antiviral is at a preclinical stage, and its effects on autophagy outside the context of EV71 infection, as well as potential off-target actions, warrant further investigation (paper). The transferability of these findings to animal models or clinical settings is not yet established. Moreover, while the mechanistic insight into BIRC3-mediated autophagy is robust, the broader applicability of targeting autophagy for antiviral therapy will require additional validation.

Research Support Resources

Researchers seeking to implement similar cell proliferation, cell cycle, or pathway inhibition assays may consider using Ribociclib succinate (SKU B1084), a selective CDK4/6 inhibitor with well-characterized solubility and storage parameters (product_spec). Ribociclib succinate is suited for antineoplastic agent studies, particularly those targeting cell cycle regulation in HER2-positive cancer models. APExBIO supplies this compound for research use only, providing flexibility for protocol design and compatibility with combination treatment studies. For detailed workflow and assay optimization, internal guides such as "Applied Workflows and Optimization of LEE011 Succinate in Cancer Research" offer practical recommendations tailored to cell proliferation and cycle arrest applications.